NCT00669825已完成1 期
A Phase 1, Two Stage, Single-Blind, Single Dose, Placebo Controlled, Dose Escalation, Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 2
- 主要终点
- Safety and Tolerability
研究概览
简要总结
ALV003-0812 is a study of the safety and tolerability of a study drug (ALV003) in healthy adult volunteers and in patients with well-controlled celiac disease, following a meal that contains gluten.
详细描述
ALV003-0812 (the FED study) is designed to evaluate the safety and tolerability of a single dose of the study drug, ALV003, administered at one of four different dose levels, and following a test meal containing a small amount (1 gram) of gluten. ALV003 has been demonstrated to proteolyze (assist with the digestion of) various forms of gluten (gluten flour, wheat bread) in laboratory studies and in animals. Celiac disease has been estimated to affect 1% of the population of the United States, is related to gluten, and has a wide range of clinical manifestations including chronic gastrointestinal symptoms, malabsorption, and bone disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Ages 18 to 45 years (inclusive)
- •Healthy volunteers, in good health on the basis of medical history, physical examination, and laboratory values to include: hematology, chemistry, urinalysis, and liver function tests.
- •Subjects with well-controlled celiac disease (CD), in good health with the exception of CD
- •history of biopsy-proven CD in past 5 years
- •on gluten free diet for at least 8 weeks prior to enrollment
- •tTG or DGP titers within normal limits (≤ 15 IU)
- •no flare in symptoms for the past 8 weeks
- •Male or non-lactating, non-pregnant females who are postmenopausal, sterile or using at least two acceptable and highly effective birth control methods
- •No systemic biologics may be taken for at least 6 months prior to Visit 2 and through 24 hours post-dose at Visit 3 Other than birth control, no prescribed medications, NSAIDs or aspirin may be taken for at least 7 days prior to Visit 2 and through 24 hours post-dose at Visit
- •No probiotics may be taken for at least 5 days prior to Visit 2 and through 24 hours post-dose at Visit
- •No over-the-counter medications and supplements may be taken for at least 3 days prior to Visit 2 and through 24 hours post-dose at Visit 3
- •Body Mass Index of < 30 kg/m2
- •Have understood and signed an Informed Consent Form
- •Able and willing to comply with study requirements
排除标准
- •Positive urine test for alcohol or illegal drugs at screening
- •Positive breath test for Helicobacter pylori
- •History (within the last 5 years) of inadequate acid secretion, either through a pentagastrin stimulated acid secretion test or fasting intragastric pH 2.5 or greater assessed by passage of a gastric pH probe in the fasting condition
- •Aspirin or nonsteroidal anti-inflammatory drugs within 7 days prior to nasogastric or orogastric intubation at Visit 2
- •The subject has received an experimental drug within 30 days
- •History of substance abuse within the past 5 years
- •Clinically significant abnormal lab values, as determined by the PI
- •Liver Function Tests > 2.5 times Upper Limit of Normal (ULN)
- •Serum Creatinine > 1.5 mg/dL
- •Hemoglobin (Hb) < 10 g/dL
- •Hematocrit outside of the normal range
- •Platelet count < 150,000
- •Serum Potassium, Prothrombin Time (PT), Partial Thromboplastin Time (PTT), or white blood cell count (WBC) outside of the normal range
- •History of tobacco use within the last 6 months
- •History of untreated or active peptic ulcer disease, esophagitis, motility disorders or any GI diseases in the past year
- •Chronic use (more than once a week) of antacids, H2 receptor blockers or proton pump inhibitors
- •Alcohol consumption of > 2 standard drinks equivalents per day
- •Positive pregnancy test within 7 days prior to study drug administration
- •Medical history (Healthy volunteers)
- •gluten intolerance
- •first degree relative diagnosed with celiac disease
- •history of food allergies or digestive enzyme deficiencies
- •history of any medically significant condition considered by PI to adversely affect participation
- •chronic disease or condition
- •Medical History (well-controlled CD subjects)
- •history of any medically significant condition (other than CD) considered by PI to adversely affect participation
- •chronic disease or condition other than CD
- •history of severe reactions to low doses of gluten/accidental exposure to gluten
- •History of a condition that is contraindicated for nasogastric or orogastric intubation
- •Known allergy or hypersensitivity to any of the components of the test meal, placebo, study drug, E. coli-derived proteins or the 25% dextrose and water solution that will be used to flush the tube immediately following dosing
研究组 & 干预措施
A
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
B
Active Comparator
ALV003 (Active Study Drug)
干预措施: ALV003 (Drug)
结局指标
主要结局
Safety and Tolerability
时间窗: Throughout
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsNCT03103412Theravance Biopharma32
暂停
1 期
Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy SubjectsHealthyNCT01340183AstraZeneca80
已完成
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy SubjectsHealthy VolunteersNCT03217604Pfizer17
终止
1 期
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)Nonalcoholic SteatohepatitisNASHNCT04565717Alnylam Pharmaceuticals6
已完成
1 期
Study of Single Ascending Doses of PF-07081532 in Healthy Adult ParticipantsHealthyNCT04148209Pfizer22